TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 729378

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive with synthetic estrogen (ethinyl estradiol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive with natural estrogens (micronized estradiol and estriol)
Number of subjects: 0
Study: 31126220

Group type: EXPERIMENTAL
Intervention: Point-light display temporal occlusion training with motor practice of the observed bowler's action, 2 sessions per week for 4 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Point-light display temporal occlusion training with motor practice of the observed bowler's action
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (only testing phases)
Number of subjects: 12
Study: 28437539

Group type: EXPERIMENTAL
Intervention: Low-dose valganciclovir hydrochloride (n=46)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Valacyclovir hydrochloride (n=34)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group with no intervention (n=44)
Number of subjects: 124
Study: 26453041

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored physical activity intervention (seven 10- to 15-min sessions over an 8-week period)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 244
Study: 23559332

Group type: EXPERIMENTAL
Intervention: 200 IU/day
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 400 IU/day
Number of subjects: 169
Study: 21157026

Group type: EXPERIMENTAL
Intervention: Galantamine (16 to 24 mg/day)
Number of subjects: 18
Study: 19692371

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (IVP) 0.3 mg every 6 weeks for 30 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Panretinal laser photocoagulation (PRP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (IVP)
Number of subjects: 20
Study: 17597085

Group type: EXPERIMENTAL
Intervention: 12-month dietary regimen
Number of subjects: 46
Study: 14724039

Group type: EXPERIMENTAL
Intervention: 50‐mg oral naltrexone
Number of subjects: 44
Study: 11431296

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12.5 mg zinc sulphate daily for six days a week for six months)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 709
Study: 9741901

Group type: EXPERIMENTAL
Intervention: New sustained-release formulation of amoxicillin (500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional gelatin capsule of amoxicillin (500 mg)
Number of subjects: 12
Study: 8285810

Group type: EXPERIMENTAL
Intervention: Manufacturer-associated NSAIDs
Number of subjects: 180

Group type: COMPARATOR
Intervention: Comparison drug
Number of subjects: 180
Study: 3172062

Group type: EXPERIMENTAL
Intervention: Bromocriptine (from puerperal day 1 to 14)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Prostaglandin E2 (from day 3 or 4 for 24 hours)
Number of subjects: 43
Study: 29604311

Group type: EXPERIMENTAL
Intervention: Formulations containing silicone particles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formulations containing Microsponge® particles (control)
Number of subjects: 0
Study: 26992875

Group type: EXPERIMENTAL
Intervention: Older individuals with SMI and diabetes
Number of subjects: 200

Group type: COMPARATOR
Intervention: Younger individuals with SMI and diabetes
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Individuals with major depressive disorder
Number of subjects: 200
Study: 24561971

Group type: EXPERIMENTAL
Intervention: Fast-track (FT) nutrition management
Number of subjects: 464

Group type: COMPARATOR
Intervention: Traditional nutrition management
Number of subjects: 464
Study: 22190010

Group type: EXPERIMENTAL
Intervention: Telehealth assessment
Number of subjects: 20

Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 20
Study: 20863241

Group type: EXPERIMENTAL
Intervention: Surface preparation with 37% phosphoric acid for 30 s
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Surface preparation with 0.5‐W Er,Cr:YSGG laser for 6 s
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: No surface preparation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional bleaching procedure (without surface preparation)
Number of subjects: 59
Study: 18851795

Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg/m2)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Glutamine (1500 mg/m2)
Number of subjects: 92
Study: 17119688

Group type: EXPERIMENTAL
Intervention: Patey technique (resection of pectoralis minor muscle)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Madden technique (preservation of pectoralis minor muscle)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 426
Study: 12534506

Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tegaderm (semipermeable membrane occlusive dressing)
Number of subjects: 0
Study: 11408134

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sub‐Tenon's anesthesia
Number of subjects: 100
Study: 9414364

Group type: EXPERIMENTAL
Intervention: Ergonomics training
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 8430216

Group type: EXPERIMENTAL
Intervention: Zopiclone 10mg (ZP)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1mg (FN)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25mg (TZ)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Levomepromazine 5mg (LP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3306904

Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg nocte)
Number of subjects: 60
Study: 29544534

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Autoinjector usability
Number of subjects: 414
Study: 29354971

Group type: EXPERIMENTAL
Intervention: Flipping moxibustion of Hui medicine combined with western medication
Number of subjects: 80

Group type: COMPARATOR
Intervention: Simple western medication (oral methotrexate and sulfasalazine)
Number of subjects: 80
Study: 25701866

Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MQAS)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine (SPAQ)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Daily proguanil
Number of subjects: 270
Study: 24149984

Group type: EXPERIMENTAL
Intervention: Totally endoscopic surgery
Number of subjects: 708

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 708
Study: 22476119

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 gm tid for 7 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ciprofloxacin 200 mg bid for 7 days
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 gm tid for 7 days (excluding Child-Pugh A and patients without ascites)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ciprofloxacin 200 mg bid for 7 days (excluding Child-Pugh A and patients without ascites)
Number of subjects: 98
Study: 18236372

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg immediately following surgery and four days postoperatively)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cyclosporin A (CSA, adapted to blood-trough level 120-150 ng/mL for six months)
Number of subjects: 20
Study: 16724499

Group type: EXPERIMENTAL
Intervention: Allevyn hydro-cellular dressings
Number of subjects: 441
Study: 12679436

Group type: EXPERIMENTAL
Intervention: Ghrelin (1.0 micro g/kg iv)
Number of subjects: 34
Study: 11028147

Group type: EXPERIMENTAL
Intervention: Cardiac pacemakers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different pacing modes
Number of subjects: 0
Study: 9364537

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2, intravenous infusion for 1 hour once every 3 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m2, intravenous infusion for 15 to 20 minutes once every 3 weeks)
Number of subjects: 200
Study: 31561652

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (20 mL) only (group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + 10 mg morphine (group BM10)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% + 15 mg morphine (group BM15)
Number of subjects: 90
Study: 29206761

Group type: COMPARATOR
Intervention: Placebo arm of an ongoing prospective clinical trial
Number of subjects: 55
Study: 27364096

Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, and polio booster vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pertussis toxoid
Number of subjects: 0
Study: 24686884

Group type: EXPERIMENTAL
Intervention: Prolongation Of Life (POL) format
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Absolute Risk Reduction (ARR) format
Number of subjects: 240
Study: 22472339

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.4 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Higher intake of folic acid (not specified)
Number of subjects: 24
Study: 18727841

Group type: COMPARATOR
Intervention: r‐hFSH and r‐hLH 0 IU/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH 25 IU/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH 75 IU/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH 225 IU/day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: r‐hFSH alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: r‐hFSH and r‐hLH (all doses)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: r‐hLH
Number of subjects: 34
Study: 16480403

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 215

Group type: COMPARATOR
Intervention: Antireflux surgery
Number of subjects: 215
Study: 12623561

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 401

Group type: COMPARATOR
Intervention: Stenting after predilatation
Number of subjects: 401
Study: 10665496

Group type: COMPARATOR
Intervention: CP-122,288 (31.25 microg intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CP-122,288 (doses between 3.125 and 312.5 microg orally)
Number of subjects: 0
Study: 9313057

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered intravenously (200 to 400 mg) or orally (500 to 750 mg) twice a day for 6 to 21 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 22
Study: 8317647

Group type: EXPERIMENTAL
Intervention: 1 g of ginger
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3549586

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bandaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plaster cast immobilisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study: 31969155

Group type: EXPERIMENTAL
Intervention: Primaquine (radical cure)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: G6PD point-of-care test
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Maternal treatment with primaquine
Number of subjects: 1
Study: 29234136

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Active vs. Sham tDCS
Number of subjects: 46
Study: 26472297

Group type: EXPERIMENTAL
Intervention: Progressive therapeutic exercise program consisting of 6 progressive therapeutic exercise modules including proprioceptive low-load progressive craniocervical and cervical exercises and high-load exercises for the neck muscles.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TENS treatment sessions (control group)
Number of subjects: 0
Study: 24825642

Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg every 2 weeks)
Number of subjects: 2067

Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg monthly)
Number of subjects: 2067

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg daily)
Number of subjects: 2067

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2067

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 2067
Study: 23186260

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 5% i.u. infusion (140 ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline i.u. infusion (140 ml)
Number of subjects: 12
Study: 20693158

Group type: EXPERIMENTAL
Intervention: gemfibrozil, niacin, and cholestyramine in combination
Number of subjects: 143

Group type: COMPARATOR
Intervention: matching placebos
Number of subjects: 143
Study: 18325911

Group type: EXPERIMENTAL
Intervention: Intervention group (IV) - received staff asthma training, advice on asthma policy, emergency beta(2)-agonist inhaler with spacer, and asthma lesson
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Intervention group (IV)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Intervention group (IV) - girls
Number of subjects: 193

Group type: COMPARATOR
Intervention: Non-intervention group (NI) - girls
Number of subjects: 193

Group type: COMPARATOR
Intervention: Non-intervention group (NI) and Intervention group (IV) - non-asthmatic peers
Number of subjects: 193
Study: 16002168

Group type: EXPERIMENTAL
Intervention: EEG asymmetry in the alpha range
Number of subjects: 99
Study: 12930247

Group type: EXPERIMENTAL
Intervention: LocaLisa three-dimensional nonfluoroscopic imaging system
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard fluoroscopy
Number of subjects: 52
Study: 10713636

Group type: EXPERIMENTAL
Intervention: Immediate processing of PBPC
Number of subjects: 68

Group type: COMPARATOR
Intervention: Overnight storage of PBPC
Number of subjects: 68
Study: 9377615

Group type: EXPERIMENTAL
Intervention: Hydrocortisone buteprate 0.1% cream
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo (cream base)
Number of subjects: 194
Study: 1545040

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 4085354

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/d
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29661838

Group type: EXPERIMENTAL
Intervention: MitoQ (20 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27770252

Group type: EXPERIMENTAL
Intervention: Simulation-based camera navigation training (camera group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Simulation-based cholecystectomy training (procedure group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 36
Study: 25697463

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometry (DXA)
Number of subjects: 89
Study: 24442048

Group type: EXPERIMENTAL
Intervention: Nutraceutical (Q10 coenzyme, Krill-oil, lipoic acid, resveratrol, Vitis vinifera seed oil, vitamin E, selenium) in addition to etanercept therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Etanercept therapy alone
Number of subjects: 40
Study: 20829340

Group type: EXPERIMENTAL
Intervention: Complete mediastinal lymphadenectomy
Number of subjects: 524
Study: 18502911

Group type: EXPERIMENTAL
Intervention: Early surgery (microdiscectomy)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Conservative treatment (intended six months of continued conservative treatment)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 283
Study: 16574893

Group type: EXPERIMENTAL
Intervention: 120 mg torcetrapib once daily for 4 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 120 mg torcetrapib twice daily for an additional 4 weeks (nonatorvastatin group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 120 mg torcetrapib on a background of atorvastatin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Atorvastatin (20 mg)
Number of subjects: 19
Study: 14627307

Group type: EXPERIMENTAL
Intervention: S(+)-ketamine/midazolam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Racemic ketamine/midazolam
Number of subjects: 100
Study: 11789169

Group type: EXPERIMENTAL
Intervention: 1000 ml gastrointestinal dialysate (non‐absorbed mannitol solution) orally 2‐3 times a day
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: XQN 5‐10 tablets 3 times per day combined with 1000 ml gastrointestinal dialysate (non‐absorbed mannitol solution) orally 2‐3 times a day
Number of subjects: 57

Group type: COMPARATOR
Intervention: Coated aldehyde oxystarch 5‐10 g, 3 times a day
Number of subjects: 57
Study: 9169964

Group type: EXPERIMENTAL
Intervention: Acetazolamide and thiamine (A + T)
Number of subjects: 33
Study: 8455235

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG) administration
Number of subjects: 94
Study: 3523636

Group type: EXPERIMENTAL
Intervention: Ornidazole (2.5 g/m2, administered orally, two times weekly for 3 weeks, total dose 15 g/m2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (administered orally, two times weekly for 3 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ornidazole (serum concentration)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ornidazole (tumour tissue concentration)
Number of subjects: 23
Study: 30739217

Group type: EXPERIMENTAL
Intervention: Breathing-retraining plus exercise-training using acoustic feedback
Number of subjects: 205

Group type: COMPARATOR
Intervention: Exercise-training alone
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Breathing-retraining plus exercise-training
Number of subjects: 205
Study: 28913570

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 269
Study: 26986188

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no TENS)
Number of subjects: 40
Study: 23410186

Group type: EXPERIMENTAL
Intervention: Phenylephrine (50 to 100 μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ephedrine (5 to 10 mg)
Number of subjects: 0
Study: 21085038

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (30% HR reserve)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (70% HR reserve)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (sedentary postpartum women)
Number of subjects: 40
Study: 19910821

Group type: EXPERIMENTAL
Intervention: Mixed-method, part-body cooling intervention (20-minute duration)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mixed-method, part-body cooling intervention
Number of subjects: 7

Group type: COMPARATOR
Intervention: No cooling intervention (Control)
Number of subjects: 7
Study: 17118491

Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free or regular) for 15 min hourly after lunch
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free or regular)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-gum
Number of subjects: 60
Study: 15789977

Group type: EXPERIMENTAL
Intervention: Colgate 360 degrees
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral‐B Indicator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crest SpinBrush PRO
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral‐B CrossAction
Number of subjects: 20
Study: 11169936

Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m2 on Day 1) plus Vinorelbine (25 mg/m2 on Days 1 and 8, every 3 weeks for a minimum of 3 cycles)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vinorelbine (30 mg/m2/week for a minimum of 9 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cisplatin plus Vinorelbine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vinorelbine alone
Number of subjects: 36
Study: 9764992

Group type: EXPERIMENTAL
Intervention: Bright basal ganglia signal intensity observed in patients
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Neuropsychiatric evaluation and psychometric tests
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Arterial ammonia levels
Number of subjects: 6

Group type: COMPARATOR
Intervention: Serum manganese concentrations
Number of subjects: 6
Study: 7909098

Group type: EXPERIMENTAL
Intervention: Advanced life support (American Heart Association guidelines) followed by intensive care to a standardised protocol
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Glasgow and Glasgow‐Pittsburgh coma scores and their constituent signs
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Absence of motor response to pain
Number of subjects: 262
Study: 3413203

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30195219

Group type: EXPERIMENTAL
Intervention: Treadmill-based gait-slip training (8 repeated slips)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal walking trials on the treadmill (control group)
Number of subjects: 43
Study: 28637494

Group type: EXPERIMENTAL
Intervention: Euiiyin-tang
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 26275653

Group type: EXPERIMENTAL
Intervention: Chlorella vulgaris extract (CVE) 1800 mg/day
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard antidepressant therapy alone (Control)
Number of subjects: 92
Study: 23219636

Group type: EXPERIMENTAL
Intervention: High-dose, high-repetition medical exercise therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-dose, low-repetition exercise therapy
Number of subjects: 42
Study: 21986283

Group type: EXPERIMENTAL
Intervention: LCI699 1.0 mg once daily
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg twice daily
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: All doses of LCI699
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 524
Study: 18712591

Group type: EXPERIMENTAL
Intervention: High levels of social support
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low levels of optimism
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High levels of optimism
Number of subjects: 77
Study: 17326594

Group type: EXPERIMENTAL
Intervention: AVINZA (morphine sulfate extended-release capsules) once a day
Number of subjects: 392

Group type: COMPARATOR
Intervention: OxyContin (oxycodone controlled-release tablets) twice a day
Number of subjects: 392